Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58
Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58
复制标题
DOI：
10.1093/jncics/pky045
复制
发表时间：
2018-10-01
影响因子：
4.4
通讯作者：
Alemany, Laia
中科院分区：
文献类型：
--
作者：
de Sanjose, Silvia;Serrano, Beatriz;Alemany, Laia
背景资料：许多国家，主要是高收入和中上收入国家，已经实施了人乳头瘤病毒（HPV）疫苗接种计划，2014年有4700万妇女接受了全程疫苗（三剂）。为了评估HPV疫苗在减少HPV相关疾病方面的潜在影响，我们旨在估计HPV类型分布以及归因于HPV类型的肛门生殖器癌和头颈部癌的负担（HPV 16/18/31/33/45/52/58/6/11）。总共从50个国家检索到18247份福尔马林固定石蜡包埋标本。采用SPF-10 PCR/DEIA/LiPA 25系统进行HPV DNA检测和分型。除宫颈癌外，HPV DNA阳性样本还进行HPV E6*I mRNA检测和/或p16（INK）（4a）免疫组织化学。结果：HPV 31/33/45/52/58与HPV 16/18/6/11联合使用，可预防近90%的宫颈癌病例。对于其他部位，HPV疫苗可预防22.8%的外阴癌、24.5%的阴茎癌、60.7%的阴道癌、79.0%的肛门癌、21.3%的口咽癌、4.0%的口腔癌和2.7%的喉癌病例。我们的估计表明，九价HPV疫苗在减少约90%的宫颈癌病例方面具有潜在影响，全球HPV病例减少50%。相关的癌症网站
Background: Many countries, mainly high- and upper-middle income, have implemented human papillomavirus (HPV) vaccination programs, with 47 million women receiving the full course of vaccine (three doses) in 2014. To evaluate the potential impact of HPV vaccines in the reduction of HPV-related disease, we aimed to estimate the HPV type distribution and burden of anogenital and head and neck cancers attributable to HPV types (HPVs 16/18/31/33/45/52/58/6/11) included in currently licensed HPV vaccines.Methods: In all, 18 247 formalin-fixed paraffin-embedded specimens were retrieved from 50 countries. HPV DNA detection and typing were performed with the SPF-10 PCR/DEIA/LiPA25 system. With the exception of cervical cancer, HPV DNA-positive samples were additionally subjected to HPV E6*I mRNA detection and/or p16(INK)(4a) immunohistochemistry. For cervical cancer, estimates were based on HPV DNA, whereas for other sites, estimates were based on HPV DNA, E6*I mRNA, and p16(INK)(4a) biomarkers.Results: The addition of HPVs 31/33/45/52/58 to HPVs 16/18/6/11 in the nonavalent HPV vaccine could prevent almost 90% of cervical cancer cases worldwide. For other sites, the nonavalent HPV vaccine could prevent 22.8% of vulvar, 24.5% of penile, 60.7% of vaginal, 79.0% of anal cancers, 21.3% of oropharyngeal, 4.0% of oral cavity, and 2.7% of laryngeal cancer cases.Conclusions: Our estimations suggest a potential impact of the nonavalent HPV vaccine in reducing around 90% of cervical cancer cases and a global reduction of 50% of all the cases at HPV-related cancer sites.